Long-Term Data Boost Novartis And Roche SMA Challenge To Biogen’s Spinraza

Rivals’ Revenues Could Overtake Spinraza In 2023

 
• By Andrew McConaghie
Zolgensma
Novartis's Zolgensma (pictured) and Roche's Evrysdi are gaining ground on Biogen's Spinraza • Source: Shutterstock

More from Business

More from Scrip